From skeletal muscle weakness to functional outcomes following critical illness: a translational biology perspective

Thorax

Volumn 74, Issue 11, 2019, Pages 1091-1098

  Batt, Jane ^a,b   Herridge, Margaret S ^b,c   Dos Santos, Claudia C ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

critical care

Indexed keywords

BORTEZOMIB; CALPAIN; CASPASE; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MUSCLE PROTEIN; MYOSIN; PROTEASOME; UBIQUITIN;

ARTICLE; AUTOPHAGY; CONVALESCENCE; CRITICAL ILLNESS; EXERCISE; FUNCTIONAL ASSESSMENT; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE UNIT; INTENSIVE CARE UNIT ACQUIRED WEAKNESS; MOBILIZATION; MUSCLE ATROPHY; MUSCLE CONTRACTILITY; MUSCLE REGENERATION; MUSCLE WEAKNESS; MYOFIBROSIS; NONHUMAN; NUTRITIONAL SUPPORT; PERIPHERAL NERVE INJURY; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN SYNTHESIS; SKELETAL MUSCLE; ANIMAL; BIOSYNTHESIS; FIBROSIS; INTENSIVE CARE; PATHOLOGY; PATHOPHYSIOLOGY; REGENERATION; TRANSLATIONAL RESEARCH;

ANIMALS; CRITICAL CARE; CRITICAL ILLNESS; FIBROSIS; HUMANS; INTENSIVE CARE UNITS; MUSCLE PROTEINS; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; PHYSICAL FUNCTIONAL PERFORMANCE; PROTEOLYSIS; REGENERATION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85071137043     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2016-208312     Document Type: Article

References (112)

1. Fan E, Cheek F, Chlan L, et al. An official American thoracic Society clinical practice guideline: The diagnosis of intensive care unit-Acquired weakness in adults. Am J Respir Crit Care Med 2014;190: 1437-46.
2. Herridge MS, Chu LM, Matte A, et al. The recover program: Disability risk groups and 1-year outcome after 7 or more days of mechanical ventilation. Am J Respir Crit Care Med 2016;194: 831-44.
3. Latronico N, Herridge M, Hopkins RO, et al. The ICM research agenda on intensive care unit-Acquired weakness. Intensive Care Med 2017;43: 1270-81.
4. Batt J, dos Santos CC, Cameron JI, et al. Intensive care unit-Acquired weakness: Clinical phenotypes and molecular mechanisms. Am J Respir Crit Care Med 2013;187: 238-46.
5. Yang T, Li Z, Jiang L, et al. Risk factors for intensive care unit-Acquired weakness: A systematic review and meta-Analysis. Acta Neurol Scand 2018;138: 104-14.
6. Yang T, Li Z, Jiang L, et al. Corticosteroid use and intensive care unit-Acquired weakness: A systematic review and meta-Analysis. Crit Care 2018;22.
7. Needham DM, Wozniak AW, Hough CL, et al. Risk factors for physical impairment after acute lung injury in a national, multicenter study. Am J Respir Crit Care Med 2014;189: 1214-24.
8. Latronico N, Rasulo FA. Presentation and management of ICU myopathy and neuropathy. Curr Opin Crit Care 2010;16: 123-7.
9. Kalamgi RC, Larsson L. Mechanical signaling in the pathophysiology of critical illness myopathy. Front Physiol 2016;7: 23.
10. Puthucheary ZA, Rawal J, McPhail M, et al. Acute skeletal muscle wasting in critical illness. JAMA 2013;310: 1591-600.
11. Ferrante LE, Pisani MA, Murphy TE, et al. Factors associated with functional recovery among older intensive care unit survivors. Am J Respir Crit Care Med 2016;194: 299-307.
12. Friedrich O, Reid MB, Van Den Berghe G, et al. The sick and the weak: Neuropathies/Myopathies in the critically ill. Physiol Rev 2015;95: 1025-109.
13. Larsson L, Li X, Edström L, et al. Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticosteroids: Mechanisms at the cellular and molecular levels. Crit Care Med 2000;28: 34-45.
14. Norman H, Zackrisson H, Hedström Y, et al. Myofibrillar protein and gene expression in acute quadriplegic myopathy. J Neurol Sci 2009;285: 28-38.
15. Llano-Diez M, Fury W, Okamoto H, et al. RNA-Sequencing reveals altered skeletal muscle contraction, E3 ligases, autophagy, apoptosis, and chaperone expression in patients with critical illness myopathy. Skelet Muscle 2019;9: 9.
16. Ochala J, Gustafson A-M, Diez ML, et al. Preferential skeletal muscle myosin loss in response to mechanical silencing in a novel rat intensive care unit model: Underlying mechanisms. J Physiol 2011;589: 2007-26.
17. Wollersheim T, Woehlecke J, Krebs M, et al. Dynamics of myosin degradation in intensive care unit-Acquired weakness during severe critical illness. Intensive Care Med 2014;40: 528-38.
18. Derde S, Hermans G, Derese I, et al. Muscle atrophy and preferential loss of myosin in prolonged critically ill patients. Crit Care Med 2012;40: 79-89.
19. Klaude M, Fredriksson K, Tjäder I, et al. Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis. Clin Sci 2007;112: 499-506.
20. Klaude M, Mori M, Tjäder I, et al. Protein metabolism and gene expression in skeletal muscle of critically ill patients with sepsis. Clin Sci 2012;122: 133-42.
21. Sandri M. Protein breakdown in muscle wasting: Role of autophagy-lysosome and ubiquitin-proteasome. Int J Biochem Cell Biol 2013;45: 2121-9.
22. Corpeno Kalamgi R, Salah H, Gastaldello S, et al. Mechano-signalling pathways in an experimental intensive critical illness myopathy model. J Physiol 2016;594: 4371-88.
23. Constantin D, McCullough J, Mahajan RP, et al. Novel events in the molecular regulation of muscle mass in critically ill patients. J Physiol 2011;589: 3883-95.
24. Dos Santos C, Hussain SNA, Mathur S, et al. Mechanisms of chronic muscle wasting and dysfunction after an intensive care unit stay. A pilot study. Am J Respir Crit Care Med 2016;194: 821-30.
25. Vanhorebeek I, Gunst J, Derde S, et al. Insufficient activation of autophagy allows cellular damage to accumulate in critically ill patients. J Clin Endocrinol Metab 2011;96: E633-E645.
26. Hussain SNA, Mofarrahi M, Sigala I, et al. Mechanical ventilation-induced diaphragm disuse in humans triggers autophagy. Am J Respir Crit Care Med 2010;182: 1377-86.
27. Llano-Diez M, Gustafson A-M, Olsson C, et al. Muscle wasting and the temporal gene expression pattern in a novel rat intensive care unit model. BMC Genomics 2011;12: 602.
28. Banduseela VC, Chen Y-W, Kultima HG, et al. Impaired autophagy, chaperone expression, and protein synthesis in response to critical illness interventions in porcine skeletal muscle. Physiol Genomics 2013;45: 477-86.
29. Nascimbeni AC, Fanin M, Masiero E, et al. Impaired autophagy contributes to muscle atrophy in glycogen storage disease type II patients. Autophagy 2012;8: 1697-700.
30. Seranova E, Connolly KJ, Zatyka M, et al. Dysregulation of autophagy as a common mechanism in lysosomal storage diseases. Essays Biochem 2017;61: 733-49.
31. Gunst J, Derese I, Aertgeerts A, et al. Insufficient autophagy contributes to mitochondrial dysfunction, organ failure, and adverse outcome in an animal model of critical illness. Crit Care Med 2013;41: 182-94.
32. Owen HC, Vanhees I, Gunst J, et al. Critical illness-induced bone loss is related to deficient autophagy and histone hypomethylation. Intensive Care Med Exp 2015;3.
33. Mei S, Livingston M, Hao J, et al. Autophagy is activated to protect against endotoxic acute kidney injury. Sci Rep 2016;6: 22171.
34. Lalazar G, Ilyas G, Malik SA, et al. Autophagy confers resistance to lipopolysaccharide-induced mouse hepatocyte injury. Am J Physiol Gastrointest Liver Physiol 2016;311: G377-G386.
35. Hermans G, Casaer MP, Clerckx B, et al. Effect of tolerating macronutrient deficit on the development of intensive-care unit acquired weakness: A subanalysis of the EPaNIC trial. Lancet Respir Med 2013;1: 621-9.
36. Fritzen AM, Madsen AB, Kleinert M, et al. Regulation of autophagy in human skeletal muscle: Effects of exercise, exercise training and insulin stimulation. J Physiol 2016;594: 745-61.
37. Banduseela VC, Ochala J, Chen Y-W, et al. Gene expression and muscle fiber function in a porcine ICU model. Physiol Genomics 2009;39: 141-59.
38. Friedrich O, Diermeier S, Larsson L. Weak by the machines: Muscle motor protein dysfunction-A side effect of intensive care unit treatment. Acta Physiol 2018;222. doi: 10.1111/apha.12885
39. Fischer D, Gang G, Pritts T, et al. Sepsis-Induced muscle proteolysis is prevented by a proteasome inhibitor in vivo. Biochem Biophys Res Commun 2000;270: 215-21.
40. Bach HH, Laporte HM, Wong YM, et al. Proteasome inhibition prolongs survival during lethal hemorrhagic shock in rats. J Trauma Acute Care Surg 2013;74: 499-507.
41. Vana PG, LaPorte HM, Wong YM, et al. Proteasome inhibition after burn injury. J Burn Care Res 2016;37: 207-15.
42. Lang CH, Huber D, Frost RA. Burn-Induced increase in atrogin-1 and MuRF-1 in skeletal muscle is glucocorticoid independent but downregulated by IGF-I. Am J Physiol Regul Integr Comp Physiol 2007;292: R328-R336.
43. Beehler BC, Sleph PG, Benmassaoud L, et al. Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation. Exp Biol Med 2006;231: 335-41.
44. Gazzerro E, Assereto S, Bonetto A, et al. Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies. Am J Pathol 2010;176: 1863-77.
45. Penna F, Bonetto A, Aversa Z, et al. Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting. J Cachexia Sarcopenia Muscle 2016;7: 345-54.
46. Agten A, Maes K, Thomas D, et al. Bortezomib partially protects the rat diaphragm from ventilator-induced diaphragm dysfunction. Crit Care Med 2012;40: 2449-55.
47. Levine B, Packer M, Codogno P. Development of autophagy inducers in clinical medicine. J Clin Invest 2015;125: 14-24.
48. Wischmeyer PE, San-Millan I. Winning the war against ICU-Acquired weakness: New innovations in nutrition and exercise physiology. Crit Care 2015;19(Suppl 3): S6.
49. Heyland DK, Stapleton RD, Mourtzakis M, et al. Combining nutrition and exercise to optimize survival and recovery from critical illness: Conceptual and methodological issues. Clin Nutr 2016;35: 1196-206.
50. Bear DE, Puthucheary ZA, Hart N. Early feeding during critical illness. Lancet Respir Med 2014;2: 15-17.
51. Heidegger CP, Berger MM, Graf S, et al. Optimisation of energy provision with supplemental parenteral nutrition in critically ill patients: A randomised controlled clinical trial. The Lancet 2013;381: 385-93.
52. Casaer MP, Wilmer A, Van Den Berghe G. Supplemental parenteral nutrition in critically ill patients. The Lancet 2013;381: 1715.
53. Morris PE, Berry MJ, Files DC, et al. Standardized rehabilitation and hospital length of stay among patients with acute respiratory failure: A randomized clinical trial. JAMA 2016;315: 2694-702.
54. Walsh TS, Salisbury LG, Merriweather JL, et al. Increased hospital-based physical rehabilitation and information provision after intensive care unit discharge: The recover randomized clinical trial. JAMA Intern Med 2015;175: 901-10.
55. Moss M, Nordon-Craft A, Malone D, et al. A randomized trial of an intensive physical therapy program for patients with acute respiratory failure. Am J Respir Crit Care Med 2016;193: 1101-10.
56. Yoon M-S. mTOR as a key regulator in maintaining skeletal muscle mass. Front Physiol 2017;8: 788.
57. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell 2017;168: 960-76.
58. Gao Y, Arfat Y, Wang H, et al. Muscle atrophy induced by mechanical unloading: Mechanisms and potential countermeasures. Front Physiol 2018;9: 235.
59. Puthucheary ZA, Astin R, Mcphail MJW, et al. Metabolic phenotype of skeletal muscle in early critical illness. Thorax 2018;73: 926-35.
60. Schiaffino S, Dyar KA, Ciciliot S, et al. Mechanisms regulating skeletal muscle growth and atrophy. FEBS J 2013;280: 4294-314.
61. Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. The Lancet 2002;360: 219-23.
62. Fredriksson K, Hammarqvist F, Strigard K, et al. Derangements in mitochondrial metabolism in intercostal and leg muscle of critically ill patients with sepsis-induced multiple organ failure. Am J Physiol Endocrinol Metab 2006;291: E1044-E1050.
63. Crouser ED, Julian MW, Blaho DV, et al. Endotoxin-Induced mitochondrial damage correlates with impaired respiratory activity. Crit Care Med 2002;30: 276-84.
64. Rooyackers OE, Gijsen AP, Saris WHM, et al. Derangement in aerobic and anaerobic energy metabolism in skeletal muscle of critically ill and recovering rats. Biochim Biophys Acta 1996;1315: 55-60.
65. Carré JE, Orban J-C, Re L, et al. Survival in critical illness is associated with early activation of mitochondrial biogenesis. Am J Respir Crit Care Med 2010;182: 745-51.
66. Wang N, Naruse K, Stamenovic D, et al. Mechanical behavior in living cells consistent with the tensegrity model. Proc Natl Acad Sci USA 2001;98: 7765-70.
67. Romanello V, Sandri M. Mitochondrial quality control and muscle mass maintenance. Front Physiol 2015;6: 422.
68. Bear DE, Parry SM, Puthucheary ZA. Can the critically ill patient generate sufficient energy to facilitate exercise in the ICU? Curr Opin Clin Nutr Metab Care 2018;21: 110-5.
69. Bear DE, Wandrag L, Merriweather JL, et al. The role of nutritional support in the physical and functional recovery of critically ill patients: A narrative review. Crit Care 2017;21.
70. Ferrie S, Allman-Farinelli M, Daley M, et al. Protein requirements in the critically ill: A randomized controlled trial using parenteral nutrition. JPEN J Parenter Enteral Nutr 2016;40: 795-805.
71. Son SM, Park SJ, Lee H, et al. Leucine signals to mTORC1 via its metabolite acetylcoenzyme A. Cell Metab 2019;29: 192-201.
72. Deane CS, Wilkinson DJ, Phillips BE, et al. "Nutraceuticals" in relation to human skeletal muscle and exercise. Am J Physiol Endocrinol Metab 2017;312: E282-E299.
73. Rocheteau P, Chatre L, Briand D, et al. Sepsis induces long-Term metabolic and mitochondrial muscle stem cell dysfunction amenable by mesenchymal stem cell therapy. Nat Commun 2015;6: 10145.
74. Walsh CJ, Batt J, Herridge MS, et al. Transcriptomic analysis reveals abnormal muscle repair and remodeling in survivors of critical illness with sustained weakness. Sci Rep 2016;6: 29334.
75. Jiang S, Li T, Yang Z, et al. AMPK orchestrates an elaborate cascade protecting tissue from fibrosis and aging. Ageing Res Rev 2017;38: 18-27.
76. Qi Y, Shang J-yi, Ma L-jun, et al. Inhibition of AMPK expression in skeletal muscle by systemic inflammation in COPD rats. Respir Res 2014;15: 156.
77. Daskalopoulos EP, Dufeys C, Bertrand L, et al. AMPK in cardiac fibrosis and repair: Actions beyond metabolic regulation. J Mol Cell Cardiol 2016;91: 188-200.
78. Chiu C-Y, Yang R-S, Sheu M-L, et al. Advanced glycation end-products induce skeletal muscle atrophy and dysfunction in diabetic mice via a RAGE-mediated, AMPK-downregulated, Akt pathway. J Pathol 2016;238: 470-82.
79. Mrozek S, Jung B, Petrof BJ, et al. Rapid onset of specific diaphragm weakness in a healthy murine model of ventilator-induced diaphragmatic dysfunction. Anesthesiology 2012;117: 560-7.
80. Picard M, Jung B, Liang F, et al. Mitochondrial dysfunction and lipid accumulation in the human diaphragm during mechanical ventilation. Am J Respir Crit Care Med 2012;186: 1140-9.
81. Ilias I, Vassiliadi DA, Theodorakopoulou M, et al. Adipose tissue lipolysis and circulating lipids in acute and subacute critical illness: Effects of shock and treatment. J Crit Care 2014;29: 1130: E5-9.
82. Marques MB, Langouche L, Endocrine LL. Endocrine, metabolic, and morphologic alterations of adipose tissue during critical illness. Crit Care Med 2013;41: 317-25.
83. Hauck AK, Bernlohr DA. Oxidative stress and lipotoxicity. J Lipid Res 2016;57: 1976-86.
84. Tamilarasan KP, Temmel H, Das SK, et al. Skeletal muscle damage and impaired regeneration due to LPL-mediated lipotoxicity. Cell Death Dis 2012;3: E354.
85. Bebernitz GR, Schuster HF. The impact of fatty acid oxidation on energy utilization: Targets and therapy. Curr Pharm Des 2002;8: 1199-227.
86. Wang XH. MicroRNA in myogenesis and muscle atrophy. Curr Opin Clin Nutr Metab Care 2013;16: 258-66.
87. De Guire V, Robitaille R, Tétreault N, et al. Circulating miRNAs as sensitive and specific biomarkers for the diagnosis and monitoring of human diseases: Promises and challenges. Clin Biochem 2013;46: 846-60.
88. Nakasa T, Ishikawa M, Shi M, et al. Acceleration of muscle regeneration by local injection of muscle-specific microRNAs in rat skeletal muscle injury model. J Cell Mol Med 2010;14: 2495-505.
89. Garros RF, Paul R, Connolly M, et al. MicroRNA-542 promotes mitochondrial dysfunction and Smad activity and is elevated in intensive care Unit-Acquired weakness. Am J Respir Crit Care Med 2017;196: 1422-33.
90. Carlson BM. The biology of long-Term denervated skeletal muscle. Eur J Transl Myol 2014;24: 3293.
91. Puthucheary Z, Rawal J, Ratnayake G, et al. Neuromuscular blockade and skeletal muscle weakness in critically ill patients: Time to rethink the evidence? Am J Respir Crit Care Med 2012;185: 911-7.
92. Wilcox SR. Corticosteroids and neuromuscular blockers in development of critical illness neuromuscular abnormalities: A historical review. J Crit Care 2017;37: 149-55.
93. Tudorascu I, Sfredel V, Riza AL, et al. Motor unit changes in normal aging: A brief review. Rom J Morphol Embryol 2014;55: 1295-301.
94. Curcio F, Ferro G, Basile C, et al. Biomarkers in sarcopenia: A multifactorial approach. Exp Gerontol 2016;85: 1-8.
95. Manini TM, Clark BC. Dynapenia and aging: An update. J Gerontol A Biol Sci Med Sci 2012;67A: 28-40.
96. Batt J, Mathur S, Katzberg HD. Mechanism of ICU-Acquired weakness: Muscle contractility in critical illness. Intensive Care Med 2017;43: 584-6.
97. Weber-Carstens S, Koch S, Spuler S, et al. Nonexcitable muscle membrane predicts intensive care unit-Acquired paresis in mechanically ventilated, sedated patients. Crit Care Med 2009;37: 2632-7.
98. Trojaborg W. Electrophysiologic techniques in critical illness-Associated weakness. J Neurol Sci 2006;242: 83-5.
99. Rich MM, Teener JW, Raps EC, et al. Muscle is electrically inexcitable in acute quadriplegic myopathy. Neurology 1996;46: 731-6.
100. Lefaucheur J-P, Nordine T, Rodriguez P, et al. Origin of ICU acquired paresis determined by direct muscle stimulation. J Neurol Neurosurg Psychiatry 2006;77: 500-6.
101. Z'Graggen WJ, Brander L, Tuchscherer D, et al. Muscle membrane dysfunction in critical illness myopathy assessed by velocity recovery cycles. Clin Neurophysiol 2011;122: 834-41.
102. Rich MM, Pinter MJ. Crucial role of sodium channel fast inactivation in muscle fibre inexcitability in a rat model of critical illness myopathy. J Physiol 2003;547: 555-66.
103. Kraner SD, Novak KR, Wang Q, et al. Altered sodium channel-protein associations in critical illness myopathy. Skelet Muscle 2012;2: 17.
104. Kraner SD, Wang Q, Novak KR, et al. Upregulation of the Cav 1.1-ryanodine receptor complex in a rat model of critical illness myopathy. Am J Physiol Regul Integr Comp Physiol 2011;300: R1384-R1391.
105. Friedrich O, Hund E, von Wegner F. Enhanced muscle shortening and impaired Ca2+ channel function in an acute septic myopathy model. J Neurol 2010;257: 546-55.
106. Guillouët M, Rannou F, Giroux-Metges M-A, et al. Tumor necrosis factor alpha induced hypoexcitability in rat muscle evidenced in a model of ion currents and action potential. Cytokine 2013;64: 165-71.
107. Guillard E, Gueret G, Guillouet M, et al. Alteration of muscle membrane excitability in sepsis: Possible involvement of ciliary nervous trophic factor (CNTF). Cytokine 2013;63: 52-7.
108. Callahan LA, Nethery D, Stofan D, et al. Free radical-induced contractile protein dysfunction in endotoxin-induced sepsis. Am J Respir Cell Mol Biol 2001;24: 210-7.
109. Friedrich O, Yi B, Edwards JN, et al. IL-1á reversibly inhibits skeletal muscle ryanodine receptor. a novel mechanism for critical illness myopathy? Am J Respir Cell Mol Biol 2014;50: 1096-106.
110. Llano-Diez M, Cheng AJ, Jonsson W, et al. Impaired Ca(2+) release contributes to muscle weakness in a rat model of critical illness myopathy. Crit Care 2016;20.
111. Salah H, Li M, Cacciani N, et al. The chaperone co-inducer BGP-15 alleviates ventilation-induced diaphragm dysfunction. Sci Transl Med 2016;8: 350ra103.
112. Truskey GA. Development and application of human skeletal muscle microphysiological systems. Lab Chip 2018;18: 3061-73.